Hepatocyte growth factor‑induced mesenchymal‑epithelial transition factor activation leads to insulin‑like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells

Liu,Rujiao; Tang,Wenbo; Han,Xiaotian; Geng,Ruixuan; Wang,Chenchen; Zhang,Zhe

doi:10.3892/ol.2018.9414

Hepatocyte growth factor‑induced mesenchymal‑epithelial transition factor activation leads to insulin‑like growth factor 1 receptor inhibitor unresponsiveness in gastric cancer cells

Authors:
- Rujiao Liu
- Wenbo Tang
- Xiaotian Han
- Ruixuan Geng
- Chenchen Wang
- Zhe Zhang
View Affiliations

Affiliations: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China, International Medical Services, Peking Union Medical College Hospital, Beijing 100000, P.R. China
Published online on: September 6, 2018 https://doi.org/10.3892/ol.2018.9414
Pages: 5983-5991
Copyright: © Liu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Insulin‑like growth factor 1 receptor (IGF‑1R) inhibitors have been developed as potential therapeutics for cancer treatment; however, the phase III trials have not produced promising overall survival rates. Therefore, understanding the mechanism underlying intrinsic resistance to IGF‑1R‑targeted agents is urgently required. A number of studies have revealed that activation of alternative receptor tyrosine kinases can mediate resistance to IGF‑1R‑targeted therapy. The present study investigated whether activated mesenchymal‑epithelial transition factor (MET; also known as c‑Met and hepatocyte growth factor receptor) confers resistance to an IGF‑1R inhibitor (NVP‑AEW541) of gastric cancer (GC) cells. NCI‑N87 and MGC‑803 cells were treated with varying concentrations and combinations of NVP‑AEW541, hepatocyte growth factor (HGF) and MET small interfering (si)‑RNA or crizotinib (a MET inhibitor). The effects of these agents on cell proliferation and pro‑apoptotic events were assessed by Cell Counting Kit‑8 assays and flow cytometry. Receptor activation and the downstream signaling pathway were examined using western blot analysis. Expression and/or activation of MET and IGF‑1R in 156 GC specimens were evaluated by immunohistochemistry. The results demonstrated that NVP‑AEW541 inhibited cell growth, with dephosphorylation of IGF‑1R and protein kinase B (AKT), in NCI‑N87 and MGC‑803 cells. Application of HGF activated MET and the downstream AKT signaling pathways, decreased apoptotic events and restored cell proliferation, which were reversed by MET inhibition via crizotinib or siRNA knockdown. Furthermore, combination therapy of NVP‑AEW541 and crizotinib exhibited an enhanced effectiveness in vitro. In addition, >40% of IGF‑1R overexpressed GC specimens showed MET expression and activation. In conclusion, HGF‑induced MET activation may represent a novel mechanism conferring unresponsiveness to IGF‑1R‑targeted agents in GC, and inhibition of MET may improve the efficacy of IGF‑1R inhibitors.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Matsubara J, Yamada Y, Hirashima Y, Takahari D, Okita NT, Kato K, Hamaguchi T, Shirao K, Shimada Y and Shimoda T: Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor and HER2 expressions on outcomes of patients with gastric cancer. Clin Cancer Res. 14:3022–3029. 2008. View Article : Google Scholar : PubMed/NCBI
3	Pollak M: The insulin and insulin-like growth factor receptor family in neoplasia: An update. Nat Rev Cancer. 12:159–169. 2012. View Article : Google Scholar : PubMed/NCBI
4	Samani AA, Yakar S, LeRoith D and Brodt P: The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocr Rev. 28:20–47. 2007. View Article : Google Scholar : PubMed/NCBI
5	Karp DD, Paz-Ares LG, Novello S, Haluska P, Garland L, Cardenal F, Blakely LJ, Eisenberg PD, Langer CJ, Blumenschein G Jr, et al: Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer. J Clin Oncol. 27:2516–2522. 2009. View Article : Google Scholar : PubMed/NCBI
6	Gualberto A and Pollak M: Emerging role of insulin-like growth factor receptor inhibitors in oncology: Early clinical trial results and future directions. Oncogene. 28:3009–3021. 2009. View Article : Google Scholar : PubMed/NCBI
7	Janjigian YY, Tang LH, Coit DG, Kelsen DP, Francone TD, Weiser MR, Jhanwar SC and Shah MA: MET expression and amplification in patients with localized gastric cancer. Cancer Epidemiol Biomarkers Prev. 20:1021–1027. 2011. View Article : Google Scholar : PubMed/NCBI
8	Inoue T, Kataoka H, Goto K, Nagaike K, Igami K, Naka D, Kitamura N and Miyazawa K: Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue. Cancer Sci. 95:803–808. 2004. View Article : Google Scholar : PubMed/NCBI
9	Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al: Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature. 487:505–509. 2012. View Article : Google Scholar : PubMed/NCBI
10	Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, et al: MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007. View Article : Google Scholar : PubMed/NCBI
11	Shattuck DL, Miller JK, Carraway KL III and Sweeney C: Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res. 68:1471–1477. 2008. View Article : Google Scholar : PubMed/NCBI
12	Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, et al: Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68:9479–9487. 2008. View Article : Google Scholar : PubMed/NCBI
13	Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, Reeves K, Chen J, Robinson D, Li A, et al: The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res. 69:161–170. 2009. View Article : Google Scholar : PubMed/NCBI
14	Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, Rosenfeld-Franklin M, Lerner L, Chiu MI, Wild R, et al: Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): Rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther. 9:2652–2664. 2010. View Article : Google Scholar : PubMed/NCBI
15	Varkaris A, Gaur S, Parikh NU, Song JH, Dayyani F, Jin JK, Logothetis CJ and Gallick GE: Ligand-independent activation of MET through IGF-1/IGF-1R signaling. Int J Cancer. 133:1536–1546. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bauer TW, Somcio RJ, Fan F, Liu W, Johnson M, Lesslie DP, Evans DB, Gallick GE and Ellis LM: Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells. Mol Cancer Ther. 5:1676–1682. 2006. View Article : Google Scholar : PubMed/NCBI
17	Bauer TW, Fan F, Liu W, Johnson M, Parikh NU, Parry GC, Callahan J, Mazar AP, Gallick GE and Ellis LM: Insulinlike growth factor-I-mediated migration and invasion of human colon carcinoma cells requires activation of c-Met and urokinase plasminogen activator receptor. Ann Surg. 241:748–758. 2005. View Article : Google Scholar : PubMed/NCBI
18	Cui JJ, Tran-Dubé M, Shen H, Nambu M, Kung PP, Pairish M, Jia L, Meng J, Funk L, Botrous I, et al: Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem. 54:6342–6363. 2011. View Article : Google Scholar : PubMed/NCBI
19	Iorio F, Knijnenburg TA, Vis DJ, Bignell GR, Menden MP, Schubert M, Aben N, Gonçalves E, Barthorpe S, Lightfoot H, et al: A landscape of pharmacogenomic interactions in cancer. Cell. 166:740–754. 2016. View Article : Google Scholar : PubMed/NCBI
20	Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol. 26:2707–2716. 2008. View Article : Google Scholar : PubMed/NCBI
21	Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, et al: Impact of MET amplification on gastric cancer: Possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep. 25:1517–1524. 2011.PubMed/NCBI
22	Ma PC, Tretiakova MS, MacKinnon AC, Ramnath N, Johnson C, Dietrich S, Seiwert T, Christensen JG, Jagadeeswaran R, Krausz T, et al: Expression and mutational analysis of MET in human solid cancers. Genes Chromosomes Cancer. 47:1025–1037. 2008. View Article : Google Scholar : PubMed/NCBI
23	Zhang H, Pelzer AM, Kiang DT and Yee D: Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res. 67:391–397. 2007. View Article : Google Scholar : PubMed/NCBI
24	Wolf S, Lorenz J, Mössner J and Wiedmann M: Treatment of biliary tract cancer with NVP-AEW541: Mechanisms of action and resistance. World J Gastroenterol. 16:156–166. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kaulfuss S, Burfeind P, Gaedcke J and Scharf JG: Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther. 8:821–833. 2009. View Article : Google Scholar : PubMed/NCBI
26	Cunningham MP, Thomas H, Marks C, Green M, Fan Z and Modjtahedi H: Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells. Int J Oncol. 33:1107–1113. 2008.PubMed/NCBI
27	Bao XH, Takaoka M, Hao HF, Wang ZG, Fukazawa T, Yamatsuji T, Sakurama K, Sun DS, Nagasaka T, Fujiwara T and Naomoto Y: Esophageal cancer exhibits resistance to a novel IGF-1R inhibitor NVP-AEW541 with maintained RAS-MAPK activity. Anticancer Res. 32:2827–2834. 2012.PubMed/NCBI
28	Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, Nadaf S, Carbone DP and Imai K: Genetic blockade of the insulin-like growth factor-I receptor: A promising strategy for human pancreatic cancer. Cancer Res. 63:6432–6441. 2003.PubMed/NCBI
29	Jaquish DV, Yu PT, Shields DJ, French RP, Maruyama KP, Niessen S, Hoover H, Cheresh A D, Cravatt B and Lowy AM: IGF1-R signals through the RON receptor to mediate pancreatic cancer cell migration. Carcinogenesis. 32:1151–1156. 2011. View Article : Google Scholar : PubMed/NCBI
30	Prenen H, Tejpar S and Van Cutsem E: New strategies for treatment of KRAS mutant metastatic colorectal cancer. Clin Cancer Res. 16:2921–2926. 2010. View Article : Google Scholar : PubMed/NCBI
31	Bai Y, Kim JY, Watters JM, Fang B, Kinose F, Song L, Koomen JM, Teer JK, Fisher K, Chen YA, et al: Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. Cancer Res. 74:7217–7228. 2014. View Article : Google Scholar : PubMed/NCBI
32	Topcu-Yilmaz P, Kiratli H, Saglam A, Söylemezoglu F and Hascelik G: Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma. Melanoma Res. 20:126–132. 2010. View Article : Google Scholar : PubMed/NCBI
33	Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K, Lauwers GY, Christensen JG, Wilner KD, Haber DA, et al: MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol. 29:4803–4810. 2011. View Article : Google Scholar : PubMed/NCBI
34	Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, et al: MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5:1837–1845. 2014. View Article : Google Scholar : PubMed/NCBI